AstraZeneca, BMS ink diabetes drug pact
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
AstraZeneca |
Bristol-Myers Squibb |
$1.05B deal |
AZ has agreed to pay BMS $100M up front and up to $950M more in milestones to partner up on two new diabetes drugs, saxagliptin and dapagliflozin. |
|
Genentech |
Seattle Genetics |
$860M development deal |
The deal is for SGN-40, a early-stage cancer treatment being studied for multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin's lymphoma. |
|
Eli Lilly |
OSI |
$385M licensing deal |
OSI has licensed the exclusive rights to PSN010--its early-stage diabetes drug--to Eli Lilly for $25 million up front and up to $360 million in milestones plus royalty payments. |
|
Genentech |
BioInvent |
$190M licensing deal |
The deal is for BioInvent's BI-204, a preclinical therapy for reducing arterial plaque. |
|
XTL Biopharmaceuticals |
DOV Pharmaceutical |
$134M licensing deal |
XTL Biopharmaceuticals is licensing DOV Pharmaceuticals' rights to bicifadine as a treatment for neuropathic pain. |
|
Biogen Idec |
Syntonix Pharmaceuticals |
$120M deal |
Biogen gains a lead product for hemophilia B and technology for developing inhalable treatments. |
|
Eli Lilly |
Nicholas Piramal India |
$100M development pact |
Nicholas Piramal will advance some of Lilly's preclinical drug candidates in clinical trials in exchange for up to $100 million in milestones and a share of the royalties. |
|
Health and Human Services |
GlaxoSmithKline |
$63.3M |
GSK has won a $63.3 million contract from HHS to develop pre-pandemic and pandemic vaccines, supporting its research into adjuvants that boost the effectiveness of vaccines. |
|
Pfizer |
Genizon BioSciences |
Licensing deal |
Pfizer has licensed the diagnostic rights involved in the genetic research of Genizon BioSciences in Alzheimer's, ADHD, and endometriosis. |
|
Wyeth Pharmaceuticals |
Pharmacopeia |
Development deal |
Wyeth has inked a pact for Pharmacopeia's JAK3 inhibitor program, which focuses on the activation of T-cells for rheumatoid arthritis, psoriasis and other immunological conditions. |
|
Wyeth Pharmceutical |
Solvay |
Development deal |
Solvay and Wyeth Pharmceutical are expanding their existing neuroscience co-development and co-commercialization agreement to include research in neuroscience. |
|
Pfizer |
Archemix |
Discovery pact |
Archemix has agreed to employ its know-how in discovering aptamer-based drugs for Pfizer. |